<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242394</url>
  </required_header>
  <id_info>
    <org_study_id>Chronic gallbladder disease</org_study_id>
    <nct_id>NCT04242394</nct_id>
  </id_info>
  <brief_title>If Chronic Gallbladder Diseases Increase the Incidence of PEC</brief_title>
  <official_title>If Chronic Gallbladder Diseases Increase the Occurence of Post Endoscopic Retrograde Choledochopancreatography Choledocholithiasis（a Prospective Multi-center Cohort Study）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-centre trial conducts at 4 ERCP centers in China designed to
      determine if chronic gallbladder diseases increase the incidence of Post-Endoscopic
      Retrograde Choledochopancreatography-Choledocholithiasis (PEC）
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic Retrograde Choledochopancreatography(ERCP) has the advantages of less injury and
      faster recovery for common bile duct stone patients. However, according to our retrospective
      study, ERCP will has a mostly 10% possibility to get an acute purulent cholecystitis which
      often requires emergency intervention, when patients combined with chronic gallbladder
      diseases, such as chronic cholecystitis, asymptomatic gallstones, and gallbladder wall
      thickness, the incidence of PEC will increase accordingly. The aim of this study is to
      observe if chronic gallbladder disease will increase the occurence of PEC and develop a
      high-risk PEC model.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 14, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Acute PEC(post-ERCP-cholecystitis )</measure>
    <time_frame>1month</time_frame>
    <description>When the PEC occurs, with right upper abdominal pain, White Blood Cell increasing, gallbladder wall ≥4mm or crudely, temperature might be more than 38 degree centigrade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Pancreatitis</measure>
    <time_frame>1month</time_frame>
    <description>Typical abdominal pain, with the level of serum amylase increasing at least 3 times of the normal range within 24 hours after ERCP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cholangitis</measure>
    <time_frame>1 month</time_frame>
    <description>Temperature should be more than 38 #, right upper abdominal pain, chills or WBC≥10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Perforation</measure>
    <time_frame>1 month</time_frame>
    <description>Typical abdominal pain,abdominal muscle tension, tenderness, evidence of free gas in abdominal cavity</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Cholecystitis</condition>
  <arm_group>
    <arm_group_label>Chronic gallbladder diseases</arm_group_label>
    <description>Routine ERCP participants with chronic gallbladder diseases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without Chronic gallbladder disease</arm_group_label>
    <description>Routine ERCP participants without chronic gallbladder diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP</intervention_name>
    <description>Routine ERCP procedures with gallbladder in situ patient</description>
    <arm_group_label>Chronic gallbladder diseases</arm_group_label>
    <arm_group_label>Without Chronic gallbladder disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Common bile duct stone ERCP patients with gallbladder in situ
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ERCP patients with gallbladder in situ

        Exclusion Criteria:

          -  Acute cholecystitis before surgery

          -  Gallbladder has been removed

          -  Gastrointestinal reconstruction

          -  Unwillingness or inability to consent for the study

          -  Unstable vital signs Coagulation dysfunction (INR&gt;1.5)

          -  Low peripheral blood platelet count (&lt;50×10 ^9 / L) or using anti-coagulation drugs

          -  Preoperative coexistent diseases: acute pancreatitis, GI tract hemorrhage, severe
             liver disease (such as decompensated liver cirrhosis, liver failure and so on), septic
             shock Biliary- duodenal fistula confirmed during ERCP

          -  Pregnant women or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenbo Meng, M.D., Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenbo Meng, M.D., Ph. D.</last_name>
    <phone>+8613919177177</phone>
    <email>mengwb@lzu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Yue, M.D., Ph. D.</last_name>
    <phone>+8615095354426</phone>
    <email>dryueping@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese herb medicine hospital of Longnan City</name>
      <address>
        <city>Longnan</city>
        <state>Gansu</state>
        <zip>746000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Zhao, M. D.</last_name>
      <phone>+8615009399289</phone>
      <email>zy1984111@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of Tianshui</name>
      <address>
        <city>Tianshui</city>
        <state>Gansu</state>
        <zip>741000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Wei, M. D.</last_name>
      <phone>+8618394231097</phone>
      <email>1904916906@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuwei turmour hospital</name>
      <address>
        <city>Wuwei</city>
        <state>Gansu</state>
        <zip>733000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linzhi Lu, M. D.</last_name>
      <phone>+8613659359016</phone>
      <email>lulinzhi2006@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cao J, Ding X, Wu H, Shen Y, Zheng R, Peng C, Wang L, Zou X. Classification of the cystic duct patterns and endoscopic transpapillary cannulation of the gallbladder to prevent post-ERCP cholecystitis. BMC Gastroenterol. 2019 Aug 5;19(1):139. doi: 10.1186/s12876-019-1053-6.</citation>
    <PMID>31382888</PMID>
  </reference>
  <reference>
    <citation>Cao J, Peng C, Ding X, Shen Y, Wu H, Zheng R, Wang L, Zou X. Risk factors for post-ERCP cholecystitis: a single-center retrospective study. BMC Gastroenterol. 2018 Aug 22;18(1):128. doi: 10.1186/s12876-018-0854-3.</citation>
    <PMID>30134864</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Wenbo Meng</investigator_full_name>
    <investigator_title>M.D., Ph. D, Direct of surgery</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>Acute purulent cholecystitis</keyword>
  <keyword>Bile duct stone</keyword>
  <keyword>Post-ERCP-Choledocholithiasis PEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecystitis</mesh_term>
    <mesh_term>Acalculous Cholecystitis</mesh_term>
    <mesh_term>Choledocholithiasis</mesh_term>
    <mesh_term>Gallbladder Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

